Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761452 | 1.00 | SRD5A2 (0.48) | SRD5A2ALDH1A1GLADHFRHTR1A | |
| SCHEMBL5585050 | 0.89 | SRD5A2 (0.62) | SRD5A2ALDH1A1GLADHFRTP53 | |
| SCHEMBL5585048 | 0.89 | SRD5A2 (0.62) | SRD5A2ALDH1A1GLADHFRTP53 | |
| SCHEMBL11451195 | 0.85 | SRD5A2 (0.46) | SRD5A2ALDH1A1GLADHFRTP53 | |
| SCHEMBL9588071 | 0.84 | ALDH1A1 (0.45) | SRD5A2ALDH1A1GLADHFRTP53 | |
| SCHEMBL11449692 | 0.82 | ALDH1A1 (0.39) | ALDH1A1GLAHTR1ARHEBPOLB | |
| SCHEMBL9535786 | 0.80 | SRD5A2 (0.42) | SRD5A2ALDH1A1GLADHFRHTR1A | |
| SCHEMBL12084282 | 0.79 | SRD5A2 (0.54) | SRD5A2ALDH1A1HTR1ARHEBPOLB | |
| SCHEMBL11457360 | 0.79 | RHEB (0.51) | SRD5A2ALDH1A1GLADHFRTP53 | |
| SCHEMBL4891430 | 0.78 | ALDH1A1 (0.55) | ALDH1A1GLAHTR1ATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629400-B2 | Image making medium | HYMAN SYDNEY | 2009-12-08 | — | — | US | disclosed |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| CN-1303074-C | Heteroarylalkylpiperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS INC (US) | 2007-03-07 | — | — | CN | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
| US-4935414-A | New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds | BEIERSDORF AG (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0297380-A2 | Indolyl propanols, process for their preparation, their uses and preparation containing them | Beiersdorf-Lilly GmbH (DE) | 1989-01-04 | — | — | EP | disclosed |
| EP-0191724-A2 | 1,4-Dihydropyridine derivatives, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1986-08-20 | — | — | EP | disclosed |
| US-4304915-A | ADRENERGIC BLOCKING AGENTS, HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS | SANDOZ LTD. (CH) | 1981-12-08 | — | — | US | disclosed |
| US-4229464-A | Aminopropanol substituted indole compounds and compositions for the treatment of cardiac and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1980-10-21 | — | — | US | disclosed |
| EP-0013878-A1 | 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1980-08-06 | — | — | EP | disclosed |
| US-4152446-A | Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1979-05-01 | — | — | US | disclosed |
| US-4146630-A | HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
| US-4076829-A | Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DT) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | SRD5A2 873/4885ALDH1A1 4327/4885GLA 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.